Company intelligence / Profile preview

Stingthera, Inc.

Ownership: Private
Development stage: Phase 3

Overview

SNX281 is currently in Phase 1 clinical trials. The drug has shown 50% stable disease among treated patients in monotherapy trials. A combination trial with Merck's Keytruda (pembrolizumab) is being conducted for patients with advanced solid tumors and lymphoma who have relapsed on or become refractory to prior immune checkpoint therapy.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

SNX281

Discontinued

Partnerships

Merck (clinical trial collaboration for SNX281 with Keytruda)

Beyond the preview

Go deeper on Stingthera, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stingthera, Inc..

Explore the full profile